 This meta-analysis suggests that three novel oral antivirals, malnupiravir, fluvoxamine and paxlovid, may be effective in reducing the mortality and hospitalization rates in patients with COVID-19. Furthermore, these three oral drugs do not appear to increase the occurrence of adverse events, suggesting that they could potentially be a breakthrough and very promising treatment for COVID-19. This article was authored by Wenwen, Chen Chen, Jakatang, and others.